Holen Sie sich die Stockscreener-App
20.30
6.84%
1.30
Vorhandelsmarkt:
20.39
0.09
+0.44%
Schlusskurs vom Vortag:
$19.00
Offen:
$18.77
24-Stunden-Volumen:
2.07M
Relative Volume:
1.18
Marktkapitalisierung:
$2.98B
Einnahmen:
$340.81M
Nettoeinkommen (Verlust:
$-419.65M
KGV:
-7.1228
EPS:
-2.85
Netto-Cashflow:
$-402.10M
1W Leistung:
+4.64%
1M Leistung:
+36.06%
6M Leistung:
+40.78%
1J Leistung:
-14.35%
1-Tages-Spanne:
$18.47
$20.48
1-Wochen-Bereich:
$17.65
$20.48
52-Wochen-Spanne:
$10.57
$26.18
Denali Therapeutics Inc Stock (DNLI) Company Profile
Firmenname
Denali Therapeutics Inc
Sektor
Branche
Telefon
(650) 866-8547
Adresse
161 OYSTER POINT BLVD., SOUTH SAN FRANCISCO
Vergleichen Sie DNLI mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
DNLI
Denali Therapeutics Inc
|
20.30 | 2.79B | 340.81M | -419.65M | -402.10M | -2.85 |
|
VRTX
Vertex Pharmaceuticals Inc
|
457.26 | 117.50B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
722.83 | 76.06B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
464.56 | 62.53B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
916.31 | 56.75B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
205.04 | 44.10B | 447.02M | -1.18B | -906.14M | -6.1812 |
Denali Therapeutics Inc Stock (DNLI) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-04-10 | Hochstufung | Cantor Fitzgerald | Neutral → Overweight |
| 2025-03-07 | Fortgesetzt | Morgan Stanley | Overweight |
| 2025-02-11 | Eingeleitet | Deutsche Bank | Buy |
| 2025-01-07 | Eingeleitet | Robert W. Baird | Outperform |
| 2025-01-03 | Eingeleitet | William Blair | Outperform |
| 2024-12-16 | Hochstufung | Stifel | Hold → Buy |
| 2024-10-10 | Fortgesetzt | Raymond James | Mkt Perform |
| 2024-10-07 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2023-12-13 | Eingeleitet | Citigroup | Buy |
| 2023-11-20 | Fortgesetzt | JP Morgan | Overweight |
| 2023-10-24 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2023-09-06 | Eingeleitet | B. Riley Securities | Buy |
| 2023-01-30 | Eingeleitet | SVB Securities | Outperform |
| 2022-12-05 | Eingeleitet | Cowen | Outperform |
| 2022-11-02 | Hochstufung | BTIG Research | Neutral → Buy |
| 2022-11-02 | Eingeleitet | BofA Securities | Buy |
| 2022-06-23 | Eingeleitet | Berenberg | Buy |
| 2021-12-10 | Fortgesetzt | Raymond James | Mkt Perform |
| 2021-09-21 | Eingeleitet | Oppenheimer | Outperform |
| 2021-09-01 | Eingeleitet | SMBC Nikko | Outperform |
| 2021-05-18 | Eingeleitet | UBS | Buy |
| 2021-02-26 | Bestätigt | H.C. Wainwright | Buy |
| 2021-02-10 | Hochstufung | Cantor Fitzgerald | Neutral → Overweight |
| 2020-11-11 | Bestätigt | H.C. Wainwright | Buy |
| 2020-10-16 | Herabstufung | BTIG Research | Buy → Neutral |
| 2020-09-14 | Fortgesetzt | JP Morgan | Overweight |
| 2020-08-20 | Bestätigt | H.C. Wainwright | Buy |
| 2020-03-13 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2020-02-28 | Hochstufung | Wedbush | Neutral → Outperform |
| 2020-02-24 | Eingeleitet | Jefferies | Buy |
| 2020-02-19 | Eingeleitet | Stifel | Hold |
| 2020-01-27 | Hochstufung | Goldman | Neutral → Buy |
| 2019-09-26 | Eingeleitet | Wedbush | Neutral |
| 2019-09-13 | Eingeleitet | Nomura | Buy |
| 2019-08-09 | Eingeleitet | BTIG Research | Buy |
| 2019-06-26 | Eingeleitet | H.C. Wainwright | Buy |
| 2018-11-15 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2018-11-12 | Eingeleitet | Janney | Buy |
| 2018-03-12 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2018-01-02 | Eingeleitet | Evercore ISI | Outperform |
| 2018-01-02 | Eingeleitet | Goldman | Neutral |
| 2018-01-02 | Eingeleitet | JP Morgan | Overweight |
| 2018-01-02 | Eingeleitet | Morgan Stanley | Overweight |
Alle ansehen
Denali Therapeutics Inc Aktie (DNLI) Neueste Nachrichten
Denali Therapeutics stock rises on $275 million royalty deal with Royalty Pharma - Investing.com
Transcript : Denali Therapeutics Inc.Analyst/Investor Day - MarketScreener
Denali Therapeutics and Royalty Pharma announce $275 million royalty funding agreement - marketscreener.com
Denali Therapeutics And Royalty Pharma Announce $275 Million Royalty Funding Agreement - TradingView
Denali Therapeutics and Royalty Pharma ink $275 million funding deal By Investing.com - Investing.com Nigeria
Denali Therapeutics enters $275 million royalty funding agreement with Royalty Pharma - Investing.com
Denali Therapeutics Secures $275M Royalty Funding Deal - TipRanks
Denali Therapeutics and Royalty Pharma ink $275 million funding deal - Investing.com India
Royalty Pharma and Denali Therapeutics Announce $275 Million Royalty Agreement for Tividenofusp Alfa Development - Quiver Quantitative
How Denali Therapeutics Inc. (4DN) stock reacts to stronger dollar2025 Trading Volume Trends & Daily Stock Trend Watchlist - Newser
Why Denali Therapeutics Inc. (4DN) stock appeals to dividend investorsJuly 2025 Reactions & Real-Time Stock Movement Alerts - Newser
Fisher Asset Management LLC Raises Stake in Denali Therapeutics Inc. $DNLI - MarketBeat
Edgestream Partners L.P. Acquires New Stake in Denali Therapeutics Inc. $DNLI - MarketBeat
Denali: Regulatory Delay Is A Strategic Opportunity (NASDAQ:DNLI) - Seeking Alpha
What technical patterns form on Denali Therapeutics Inc. (4DN) stock chartsQuarterly Risk Review & Expert Curated Trade Setup Alerts - Newser
How Denali Therapeutics Inc. (4DN) stock performs in easing cyclesJuly 2025 Setups & Safe Swing Trade Setup Alerts - Newser
Denali Therapeutics (DNLI) Stock Analysis Report | Financials & Insights - Benzinga
What risks investors should watch in Denali Therapeutics Inc. stockTrade Volume Report & Free Growth Oriented Trading Recommendations - BỘ NỘI VỤ
Groupama Asset Managment Buys 31,043 Shares of Denali Therapeutics Inc. $DNLI - MarketBeat
Can Denali Therapeutics Inc. (4DN) stock sustain institutional flowsJuly 2025 News Drivers & AI Powered Trade Plan Recommendations - BỘ NỘI VỤ
Denali Therapeutics announces board and leadership changes By Investing.com - Investing.com Nigeria
Transcript : Denali Therapeutics Inc. Presents at Stifel 2025 Healthcare Conference, Nov-12-2025 08 - MarketScreener
Trading the Move, Not the Narrative: (DNLI) Edition - news.stocktradersdaily.com
Published on: 2025-11-28 01:22:18 - BỘ NỘI VỤ
Is Denali Therapeutics Inc. stock a good choice for value investorsMarket Weekly Review & Daily Volume Surge Trade Alerts - moha.gov.vn
Geode Capital Management LLC Grows Position in Denali Therapeutics Inc. $DNLI - MarketBeat
Growth Recap: Is Denali Therapeutics Inc. stock positioned for digital transformationJuly 2025 Price Swings & AI Optimized Trading Strategy Guides - BỘ NỘI VỤ
Will Denali Therapeutics Inc. stock reach all time highs in 2025Market Sentiment Summary & Long-Term Growth Stock Strategies - BỘ NỘI VỤ
Segall Bryant & Hamill LLC Increases Stock Position in Denali Therapeutics Inc. $DNLI - MarketBeat
Transcript : Denali Therapeutics Inc. Presents at Jefferies London Healthcare Conference 2025, Nov-18-2025 12 - marketscreener.com
How Denali Therapeutics Inc. stock trades during market volatility2025 Volatility Report & Reliable Trade Execution Plans - newser.com
How risky is Denali Therapeutics Inc. (4DN) stock compared to peers - newser.com
How strong dollar benefits Denali Therapeutics Inc. (4DN) stockJuly 2025 Trends & Community Consensus Picks - newser.com
Denali Therapeutics Inc. (4DN.MU) Stock Price, News, Quote & History - Yahoo! Finance Canada
Why Denali Therapeutics Inc. (4DN) stock benefits from AI revolution2025 Stock Rankings & Real-Time Volume Triggers - newser.com
Is Denali Therapeutics Inc. (4DN) stock at risk of policy regulationTrade Risk Report & AI Based Buy and Sell Signals - newser.com
Is Denali Therapeutics Inc. stock a defensive play in 2025Market Risk Summary & Risk Managed Investment Strategies - newser.com
Will Denali Therapeutics Inc. stock gain from lower inflationSwing Trade & High Conviction Investment Ideas - newser.com
Is Denali Therapeutics Inc. stock a contrarian buy2025 Trade Ideas & Accurate Buy Signal Notifications - newser.com
Is Denali Therapeutics Inc. (4DN) stock positioned for digital growth eraQuarterly Investment Review & Capital Efficient Trade Techniques - newser.com
Published on: 2025-11-19 17:06:18 - newser.com
Can Denali Therapeutics Inc. (4DN) stock resist broad market declinesTrade Exit Summary & Weekly Stock Breakout Alerts - newser.com
Applying sector rotation models to Denali Therapeutics Inc.Quarterly Risk Review & Weekly Return Optimization Alerts - newser.com
Is Denali Therapeutics Inc. stock supported by strong cash flowsEarnings Miss & Daily Volume Surge Trade Alerts - newser.com
Will Denali Therapeutics Inc. (4DN) stock outperform small cap peers2025 Price Momentum & Reliable Trade Execution Plans - newser.com
Finanzdaten der Denali Therapeutics Inc-Aktie (DNLI)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.10%
1.10%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):